Wed, Mar 4, 2015, 4:10 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

ouch_yikes 164 posts  |  Last Activity: Feb 26, 2015 3:10 PM Member since: Feb 23, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    To the new newbies....

    by ouch_yikes Feb 23, 2015 12:45 PM
    ouch_yikes ouch_yikes Feb 26, 2015 3:10 PM Flag

    Please do your own due diligence...Nothing is a guarantee...Perhaps, the main reason I choose to own this biotech is that it has numerous shots on goal and many of the decisions will come before end of the decade, however, if none ever get approved, this will not be a spectacular investment...Investing is essentially speculating and constant re-evaluation...

  • Reply to

    Credibility

    by tartiaboy Feb 24, 2015 10:47 AM
    ouch_yikes ouch_yikes Feb 24, 2015 1:12 PM Flag

    Credibility issue or not, this biotech always seems to be grossly undervalued. It may take an eventual full blown buyout acquisition by a big pharma to finally receive something nice and fair and at premium....I realize hindsight is 20/20, but reflecting back...... When the stock took off(from ~2008-2011) and moved well into the teens, Tartia may have been better off trimming half his position and today he could be watching with the houses money and re-establishing any more amount in re-entry funds with those previous profits at his leisure....Such is the volatile world of small cap investing because that would have been a huge mistake to do with PCYC or QCOR or JAZZ or countless others.....I did profit take back in 2011 or '12, but I should have sold half and let the rest ride with all the houses money on the line...freeing up capital and remaining nimble to make money elsewhere.....

  • Reply to

    Credibility

    by tartiaboy Feb 24, 2015 10:47 AM
    ouch_yikes ouch_yikes Feb 24, 2015 12:37 PM Flag

    I don't deny the base salaries/raises/bonuses are utterly outrageous for a biotech that has failed to enhance shareholder valuations for three years and now this...A private company actually has to produce a healthy amount of profits in order to distribute bonuses and give raises...

    That said, how can you call the fairly stable and consistent several hundred million dollar annual revenue contribution mix worthless?

  • ouch_yikes ouch_yikes Feb 24, 2015 9:42 AM Flag

    You can mention all the so called alleged "failures", but, at the end of the day, though unexciting as they might be, they still have a nice five-drug revenue contribution mix that should continue to throw off several hundred million dollars annually: Belinodaq/Folotyn/Fuselev/Zevalin/MarQibo and a potential sixth with CE Melph...They ALSO have a potential NDA coming up for APAZ and several much more substantial indications for MarQibo being trialed and concluding later in decade and, of course, SP-1620...So, no, I wouldn't exactly say everything is ALL about SP-2012 as last "dawn of hope"....They COULD conceivably continue to get larger drug population niches approved(several hundred million dollar) and grow their franchises(via CASI and NDA's and such), but that is the slower path OR finally get ONE big one, one potential blockbuster through the trials and on to successful approval: SP-2012 or SP-1620

  • ouch_yikes ouch_yikes Feb 23, 2015 2:46 PM Flag

    Who were the ones selling in the $5's? Its like dumping AAPL at $5 in 2002.....

  • Reply to

    To the new newbies....

    by ouch_yikes Feb 23, 2015 12:45 PM
    ouch_yikes ouch_yikes Feb 23, 2015 2:22 PM Flag

    Worst case scenario is all their drugs fail to get an approval in which case they should still be able to produce ~$150M-200M/Y....IF, on the other hand, orphan status is, in fact, real, the only difference would be a potential slight competitive threat by a desperate generic ~2019, however, they have many other shots on goal....other drugs moving through their pipeline, one(SP-2012) that could compete in a $6 BILLION market place...They are stoked about it and from what data I've seen come out on the drug, so am I!

  • ouch_yikes ouch_yikes Feb 23, 2015 1:59 PM Flag

    IMO, Sandoz must be either desperate or #$%$ to be contesting a protected orphan drug that expires so far from now. If orphan status is real, its not even worth appealing!....What a waste of lawyer fees...Besides, so, being a generic, they encroach on the hospital setting and do battle with Sagent....big deal.......Community setting is cozy and tight with the real deal....

  • Reply to

    To the new newbies....

    by ouch_yikes Feb 23, 2015 12:45 PM
    ouch_yikes ouch_yikes Feb 23, 2015 1:46 PM Flag

    Yet, you can't refute one sentence of the post at all and, even worse, can't recommend one of the "thousands of other stocks out there" to replace this with, right?...Were you part of that upside roadkill because I have been seeing the bashers get utterly slaughtered since this was a penny stock...It may be slow, but smart money who buys the incredible gift dips this biotech takes every three years makes huge windfalls later

  • ouch_yikes ouch_yikes Feb 23, 2015 1:36 PM Flag

    Seriously, you seem to always be all over Markbuti on his position..is it so much to ask which of the analysts you think will be most accurate?...The one with the $12, the one with the $7? or the one who maintains $15? To help you make this decision and to be fair and most conservative, I would toss out the lowest and highest and stay safely in the middle...so $12? which is currently STILL over +100% upside?!?!?...that aint a "fun" trade, that is more than a double!

  • ouch_yikes ouch_yikes Feb 23, 2015 1:18 PM Flag

    How long did it take AAPL to resurrect from the dead? So, for the record, Who are you betting on, Roth or Wainwright in accuracy? I say, Wainwright is underestimating the situation......

  • ouch_yikes ouch_yikes Feb 23, 2015 1:13 PM Flag

    ...Wainwright holds $15...who you betting on will be most accurate? Just sayin'...

  • Reply to

    To the new newbies....

    by ouch_yikes Feb 23, 2015 12:45 PM
    ouch_yikes ouch_yikes Feb 23, 2015 1:08 PM Flag

    Hey, Xerox gave Bill Gates the world...It happens..Today, it happened here.....

  • Reply to

    To the new newbies....

    by ouch_yikes Feb 23, 2015 12:45 PM
    ouch_yikes ouch_yikes Feb 23, 2015 12:58 PM Flag

    Imagine, those who sold in the $5's gave it away letting others have a free unexpiring call option on several potential blockbusters!

  • ouch_yikes by ouch_yikes Feb 23, 2015 12:45 PM Flag

    This is a biotech that has, at current levels, absolutely tremendous upside as long as current revenues remain stable and the current five drug revenue contributions flow stable up thru 2018, the down-side risk is practically nil, nada,...

    At the current ludicrous price, this is essentially a FREE, un-expiring call option on several potential blockbusters that may or may not come through before this decade concludes!

    However, with ALL that said...

    The CEO is, IMO, unpopular and shorts LOVE hating this CEO......Short interest is usually off the charts high....

    The problem is, shorts have been at this stock since it was in the pennies....and this biotech always eventually seems to turn them into upside roadkill.....

    You don't have to like him(Hell, Steve Jobs wasn't exactly a favorite!)....bet do not bet against him...

  • ouch_yikes ouch_yikes Feb 23, 2015 12:24 PM Flag

    If they re-instated the buyback program today, so much easier to reach triple digits later on....with SP-2012 :)

  • Reply to

    A ONE DAY NON EVENT.......,,,,,,,,,

    by sherrysgone3 Feb 23, 2015 11:50 AM
    ouch_yikes ouch_yikes Feb 23, 2015 12:20 PM Flag

    JoeSoloman has been more accurately right than anyone else around and to be prescient in this equity is about as hard a task as it gets..He, or Tartia should replace Raj...Instant double-digits or twenties would imminently follow....

  • ouch_yikes ouch_yikes Feb 23, 2015 12:15 PM Flag

    So, an analyst that finally "gets it"....Essentially: non-event until 2019

  • Reply to

    Compensatory Arrangements

    by dcaf7 Feb 22, 2015 5:48 PM
    ouch_yikes ouch_yikes Feb 23, 2015 10:16 AM Flag

    The "compensation committee" seems to have forgotten that one of the largest catalysts and milestone achievement goals for the year 2014(that would be the APAZ NDA filing and PHASE III) never even happened! LOL....So, how could they say substantially ALL major goals accomplished?!?!?

    ALSO, to compare revenue growth improvements based on nothing more than the Fuselev glut work down having finally come to an official end in 2014..... is absurd....So far(three quarter into 2014): Zevalin sales were dismal, Folotyn remained in its expected range(there wasn't any marked improvement) and MarQ shows its just a small niche until FDA approves larger population bases via their two trials and eventual NDA's.........

    Positives were successful the CE Melph trial and its NDA filing(which was about as late as possible in its filing in the year), Belinodaq getting approved and SP-2012 "go" decision, with a lack of full public PHASE II data available.....but coming soon in Q2... With the stock down so much, IMO, hardly worth the justification of any bonuses, nor raises...

  • ouch_yikes ouch_yikes Feb 23, 2015 8:12 AM Flag

    Actually, expect to hear more elaboration tomorrow at the RBC conference...IMO, its WAY too premature for analysts to be jumping out in front with downgrading...For example, IF orphan status upholds thru 2018, there couldn't possibly be another generic threat until 2019(other than osteosarcoma, which they wouldn't even bother with). How can anyone take away orphan status, unless it wasn't really granted to begin with?!..I think the $5's and $6's levels will be very short-lived stays...Perhaps the the high short interest positions will cover and manipulation can finally come to an end now....

  • This biotech's stock price has suffered so much deteriorating erosion over the last three years(and I shutter to think at what price its gonna open up Monday morning)...

    ..... yet, according the filing that came out Friday AH, the upper management is receiving, not only bonuses, but salary increases?

    So, let me get this straight(and correct me if I am wrong):

    When the stock price actually rises and shows green for the year(its been a long, long, LONG time since THAT has actually successfully occurred with this biotech!), you can go ahead and base compensation and bonuses on some kind of external measurement: the stock price actually moving up in market cap...and you can then put it into a category and league, so that which you then can compare it to other biotechs, calling it their "peers" and you actually hire third party surveyors to scout around looking for the very highest paid in their industry with similar market caps to justify the excessively high salaries?

    .....YET..... when the stock price goes nowhere but down, down, and then down some more, the metric then completely shifts to some kind of internal measurement, like their easy, low bar, no brainer lay up catalysts?

    Because, if the market cap is only a third of what it once was(was $1B in 2011!), one-third the amount in just salaries and complete and utter dismissal of bonuses and other forms of completely unjustifiable compensation would put a crimp in the reality of what the shareholders actually see in the worth of their dwindling holdings?

    IMO, this current latest version of the so called compensation committee needs to get booted out ASAP...Activists HAVE to seize control of the BOD to actually lead fiduciary shareholder responsibilities...IMO, its imperative....

    Shareholders should see significant stock price valuation increases before any bonuses and raises are given, delivered, and earned to upper management....NOT the exact OPPOSITE!

SPPI
6.305+0.245(+4.04%)4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.